

# NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Scoping

#### **STA – Pertuzumab in combination with trastuzumab and docetaxel for the treatment of HER2 positive metastatic or locally recurrent unresectable breast cancer**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
---

No potential equality issues were identified during the scoping process.
--

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?
---

N/A
-----

3. Has any change to the draft scope been agreed to highlight potential equality issues?
--

N/A
-----

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes
---

Technology Appraisals: Scoping

Equality impact assessment for the single technology appraisal of pertuzumab in combination with trastuzumab and docetaxel for the treatment of HER2 positive metastatic or locally recurrent unresectable breast cancer

Issue date: January 2013

to the matrix been made?
N/A

**Approved by Associate Director:** Janet Robertson

**Date:** 23/11/2012